WO2008070176A1 - Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents - Google Patents

Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents Download PDF

Info

Publication number
WO2008070176A1
WO2008070176A1 PCT/US2007/025056 US2007025056W WO2008070176A1 WO 2008070176 A1 WO2008070176 A1 WO 2008070176A1 US 2007025056 W US2007025056 W US 2007025056W WO 2008070176 A1 WO2008070176 A1 WO 2008070176A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
phosphate derivative
compound
och
derivative according
Prior art date
Application number
PCT/US2007/025056
Other languages
French (fr)
Inventor
Sheng-Chu Kuo
Che-Ming Teng
Kuo-Hsiung Lee
Li-Jiau Huang
Li-Chen Chou
Chih-Shiang Chang
Chung-Ming Sun
Tian-Shung Wu
Shiow-Lin Pan
Tzong-Der Way
Jang-Chang Lee
Jing-Gung Chung
Jai-Sing Yang
Chien-Ting Chen
Ching-Che Huang
Shih-Ming Huang
Original Assignee
China Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP07853279A priority Critical patent/EP2096924B1/en
Priority to CA2670292A priority patent/CA2670292C/en
Priority to NZ577130A priority patent/NZ577130A/en
Priority to US12/448,088 priority patent/US8440692B2/en
Priority to KR1020097014196A priority patent/KR101139413B1/en
Priority to CN2007800447969A priority patent/CN101583280B/en
Application filed by China Medical University filed Critical China Medical University
Priority to AU2007328034A priority patent/AU2007328034B2/en
Priority to JP2009540310A priority patent/JP5102843B2/en
Publication of WO2008070176A1 publication Critical patent/WO2008070176A1/en
Priority to US13/892,576 priority patent/US9023867B2/en
Priority to US13/892,545 priority patent/US9029394B2/en
Priority to US13/892,522 priority patent/US9023866B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems

Definitions

  • the present invention relates to novel phosphate derivatives of 2-aryl-4-quino!ones, and novel intermediates, 2-selenophene 4-quinolones and ⁇ /, ⁇ /-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones; and in particular to their uses in treating human cancers.
  • R 6 , R 3 ' F, Cl, OCH 3
  • Preferred embodiments of the present invention include (but not limited thereto) the following items:
  • a phosphate derivative of 2-aryl-4-quinolone having the following formulas Ia, Ib or Ic:
  • R 2 ', R 3 ', R4 1 , Rs' and R 6 ' independently are H, (CH 2 )nCH 3 , (CH 2 ) n YH, Y(CH 2 ) n CH 3 , Y(CH 2 ) n YH, Y(CH 2 ) n NR 8 R 9 , X, (CH 2 ) n NR 8 R 9 ,
  • n is an integer of 0-4, Y is 0 or S, X is F, Cl, or Br 1 and R 8 and R 9 independently are H, (CH 2 ) n YH, (CH 2 ) n N(C n H 2n+ i)(C m H 2m+1 ) or (CH 2 ) n CH 3 , wherein n and Y are defined as above, and m is an integer of 0-4; R 2 , R 3 , R 4 and R 5 independently are H, (CH 2 ) n CH 3 , (CH 2 ) n YH,
  • R 3 and R 4 together is -Y(CH 2 ) n Y-, wherein n, Y, X, R 8 and R 9 are defined as above; and R 1 and R 1 1 independently are H, Li + , Na + , K + , N + R 8 R 9 R 10 Rn or benzyl wherein R 10 and R 11 independently are H, (CH 2 ) n YH, (CH 2 ) n N(C n H 2n+1 )(C m H 2m+1 ) or (CH 2 ) n CH 3 , n, m, R 8 and R 9 are defined as above.
  • R 2 , R 3 , R 4 , and R 5 are all H; or one of R 2 , R 3 , R 4 , and R 5 is F, OCH 3 , Y(CH 2 ) n CH 3 or (CH 2 J n NR 8 Rg, and the others thereof are H; or R 2 and R 5 are H, and R 3 and R 4 together is -O(CH 2 ) n O-, wherein n, Y 1 R 8 and R 9 are defined as in Item 1.
  • R 2 , R 3 and R 5 are H; and R 5 ' is F, and R 2 ', R 3 ', R 4 ' and R 6 'are H.
  • R 4 , and R 5 are all H; or one of R 2 , R 3 , R 4 and R 5 is F or OCH 3 , and the others thereof are H; or R 2 and R 5 are H, and R 3 and R 4 together is -0(CH 2 J n O-, wherein n is defined as in Item 1.
  • a pharmaceutical composition for the killing of solid cancer cells which comprises a therapeutically effective amount of a phosphate derivative of 2-aryl-4-quinolone as set forth in any one of Item 1 to Item 19 or a pharmaceutically acceptable salt thereof, as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.
  • composition according to Item 20 wherein the solid cancer cells are human breast cancer, colon cancer, lung cancer, renal cancer, hepatoma, or leukemia cancer
  • R 2 ', R 3 ' and R 4 ' independently are H, (CH 2 ) n CH 3 , (CH 2 ) n YH, Y(CH 2 )nCH 3 , Y(CH 2 ) n YH, Y(CH 2 ) n NR 8 R 9l X, or (CH2) n NR 8 R 9 , wherein n is an integer of 0-4, Y is O or S, X is F, Cl, or Br, and Re and R 9 independently are H, (CH 2 ) n YH, (CH 2 ) n N(C n H 2n+ i )(C m H 2m+1 ) or (CH 2 ) n CH 3 , wherein n and Y are defined as above, and m is an integer of 0-4; R 2 , R 3 , R 4 and R 5 independently are H, (CH 2 ) n CH 3 , (CH 2 ) n YH, Y(CH 2
  • R 3 and R 4 together is -Y(CH 2 J n Y-, wherein n, Y, X, R 8 and R 9 are defined as above.
  • R 2 , R 3 , R 4 , and R 5 are all H; or one of R 2 , R 3 , R 4 and R 5 is F or OCH 3 , and the others thereof are H; or R 2 and R 5 are H, and R 3 and R 4 together is -O(CH 2 ) n O-, wherein n is defined as in Item 19.
  • R 2 ', R 3 ' and R 4 ' are all H; or one of R 2 ', R 3 ' and R 4 ' is F or OCH 3 , and the others thereof are H.
  • a pharmaceutical composition for the killing of solid cancer cells which comprises a therapeutically effective amount of a compound of 2-selenophene 4-quinolone as set forth in any one of Item 23 to Item 27 or a pharmaceutically acceptable salt thereof, as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.
  • R 2 ', R 3 ', R 4 1 , R 5 ' and R 6 ' independently are H, (CH 2 )nCH 3 , (CH 2 ) n YH,
  • n is an integer of 0-4, Y is O or S, X is F, Cl, or Br, and R 8 and Rg independently are H, (CH 2 ) n YH, (CH 2 ) n N(C n H 2n+1 )(C m H 2m+1 ) or (CH 2 ) n CH 3 , wherein n and Y are defined as above, and m is an integer of 0-4; R 2 , R 3 , R 4 and R 5 independently are H, (CH 2 ) n CH 3 , (CH 2 ) n YH, Y(CH 2 ) n CH 3 , Y(CH 2 )nYH, Y(CH 2 ) n NR 8 R 9 , X, (CH 2 ) n NR 8 R 9 , or R 3 and R 4 together is -Y(CH 2 ) n Y-, wherein n, Y 1 X, R 8 and R 9 are defined as above; provided that one of
  • a pharmaceutical composition for the killing of solid cancer cells which comprises a therapeutically effective amount of a compound of 2-phenyl 4-quinolone as set forth in any one of Item 30 to Item 35 or a pharmaceutically acceptable salt thereof, as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.
  • Fig. 1 shows effects of compound 1-1 and compound 1-1 -b on MCF7 tumor growth in a mouse xenograft model.
  • Female SCID mice received injections of MCF7 transfectants to induce tumor xenografts. Mice were divided into five groups. The second to fifth groups were given i.p. with compounds 1-1 (15 mg/kg), 1-1 (30 mg/kg), 1-1 -b (22.5 mg/kg), and 1-1 -b (45 mg/kg), respectively, three times per week. Data are expressed as mean of tumor weights (g) ⁇ S. E. M. * p ⁇ 0.05 compared with the control.
  • Fig. 2 shows effect of compound 1-1 -b on animal survival.
  • BALB/c mice were intraperitoneal ⁇ injected with CT-26 tumor cells for 7 days before beginning the treatments with compound 1-1 -b (5 mg/kg/day and 10 mg/kg/day QD x 7).
  • Fig. 3 shows effect of quinolone derivatives on the viability of human breast cancer cells.
  • MCF7 cells were treated with DMSO (Control) or various concentrations (0.125 ⁇ M to 10 ⁇ M) of quinolone derivative for 48 hours and subsequent cell viability was measured by MTT assay. Results from three separate experiments were averaged and are presented as mean ⁇ standard error as shown.
  • Example 7 a novel intermediate, 2-selenophene 4-quinolone (l-7-d), was synthesized. 2-selenophene-4-quinolone (l-7-d) was reacted with tetrabenzyl pyrophosphate in the presence of alkali, the corresponding phosphoric acid dibenzyl ester (l-7-e) was obtained.
  • l-7-d 2-selenophene 4-quinolone
  • HBr (3ml) was added while the solution was heated to 60 0 C, and the mixture was heated to 90 0 C for 3h. After the reaction was complete, the reaction mixture was poured into water, and extracted with EtOAc. The acid layer was neutralized to pH 7-8 by adding 10% NaHCO 3 , and extracted with EtOAc (100ml x 5). The organic layer was dried over MgSO 4 , and evaporated. The residue was recrystallized from n-hexane-EtOAc to afford l-8-d as gray solid (55mg, 59.9%).
  • 1-10-c (530mg, 2mmol), ⁇ /-bromo-succinimide (NBS, 360mg, 2 mmol), and 2,2'-azobis(isobutyronitrile) (AIBN, 30 mg, 0.19 mmol) were added to a dry round bottom flask, which was purged with argon. 50 ml of dry benzene was added to the reaction mixture in an argon atmosphere with stirring at room temperature for 30 min, and then refluxed at 80 0 C for 1 h and then cooled to room temperature to give 1-10-d, which, without further purification, was treated with diethylamine (3.0 ml, 29.0 mmole), and then refluxed for 1 h.
  • diethylamine (3.0 ml, 29.0 mmole
  • mice Female GALB/cAnN-Foxn1.E SCID mice (18-20 g; 6-8 weeks of age) were purchased from the National Animal Center and maintained in pressurized ventilated cage according to institutional regulations. The mice were implanted subcutaneously with estradiol (0.7mg) 2 days before tumor transplantation. MCF-7 cells (2 ⁇ 10 6 ) were inoculated s.c. into the right flank of the mice. After appearance of a 150-mm 3 tumor nodule, 30 tumor-bearing mice were randomly divided into five groups for treatment with vehicle (PBS), 1-1 or 1-1 -b. The first groups only received vehicle. The second to fifth groups were given i.p.
  • PBS vehicle
  • 1-1 or 1-1 -b vehicle
  • mice 30 male 6-week-old Balb/c mice, were purchased from the National Animal cancer and maintained in pressurized ventilated cage according to institutional regulations.
  • II-2 Results 11-2-1 Appearance of mice after treatment
  • mice in the excipient control group showed overt ascites, while mice receiving orally 1-1 -b (5 mg/kg/day, QD x 7) and 1-1 -b (10 mg/kg/day, QD x 7) exhibited reduced ascites development.
  • II-2-2 The average life span of mice after treatment As shown in Fig. 2, all mice in the excipient control group were dead
  • MTT solution (2 mg/ml, Sigma Chemical Co.) was added to each well to make a final volume of 500 ⁇ and incubated for 1 h at
  • compound l-7-d In vitro cytotoxic activity of compound l-7-d was tested in HCT-116, Hep G2, NCI-H226, A549, A498 and HL-60 cells. As shown in Table 1 , compound l-7-d demonstrates significant inhibition against most of the six cancer cell lines and most notably, is quite active against HCT-116 and HL-60 cells. Compound l-7-d shows an IC 50 of 0.9 ⁇ M against HCT-116 and an IC 50 of 0.5 ⁇ M against HL-60 cell. Compound l-7-d is an attractive candidate for development as a novel anti-cancer agent.
  • IC 50 value means the concentration causing 50% growth-inhibitory effect.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and Λ/, Λ/-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

Description

Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
Field of the Invention
The present invention relates to novel phosphate derivatives of 2-aryl-4-quino!ones, and novel intermediates, 2-selenophene 4-quinolones and Λ/, Λ/-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones; and in particular to their uses in treating human cancers.
Background of the Invention Quinolone derivatives were initially discovered as the agents to act on bacterial DNA gyrase, and thus developed as anti-bacterial agents. Recently DNA topoisomerase Il has emerged as the pharmacological target for this class of quinolone compounds. We have synthesized a series of substituted 2-phenyl-4-quinolone (A) which appeared to function as novel antimitotic agents. [Kuo, S. C, Lee, H. Z., Juang, J. P., Lin, Y. T., Wu, T. S., Chang, J. J., Lednicer, D., Paull, K. D., Lin, C. M., Hamel, E. Synthesis and cytotoxicity of 1 ,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin. J. Med. Chem. 1993, 36, 1146-56; Li, L., Wang, H. K., Kuo, S. C, Wu, T. S., Mauger, A., Lin. C. M., Hamel, E. Lee, K. H. Antitumor agents. 155. Synthesis and biological evaluation of 3', 6, 7- substituted 2-phenyl-4-quinolones as antimicrotubule agents. J. Med. Chem. 1994, 37, 3400-7] Later on we continued to synthesize many related analogs such as 2-phenylnaphthyridine-4-ones (B) [Chen, K., Kuo, S. C, Hsieh, M. C, Mauger, SA., Lin, C. M., Hamel, E., Lee, K. H. Antitumor agents. 174. 21,3',4I,5,6,7-Substituted 2-phenyl-1 ,8-naphthyridin-4- ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. 1997, 40, 2266-75], 2-phenyl-4-quinazolones (C) [Xia, Y., Yang, Z. Y., Hour, M. J., Kuo, S. C, Xia, P., Bastow, K. F., Nakanishi, Y., Namrpoothiri, P., Hackl, T., Hamel, E., Lee, K. H. Antitumor Agents. Part 204: Synthesis and Biological Evaluation of Substituted 2-Aryl Quinazolinones, Bioorg. Med. Chem. Lett. 2001 , 11, 1193-6; Hour, M. J., Huang, L. J., Kuo, S. C, Xia, Y., Bastow, K. F., Nakanishi, Y., Hamel, E., Lee, K. H. 6-Alkylamino- and 2,3-dihydro-3'-methoxy-2-phenyl-4- quinazolinones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. 2000, 43, 4479-87] and tetrahydro-2-phenyl- 4-quinolones (D) [Xia, Y, Yang, Z. Y., Xia, P., Bastow, K. F., Tachibana, Y., Kuo, S. C, Hamel, E., Hackl. T., Lee, K. H. Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3l,4I-substituted-1 ,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents. J. Med. Chem. 1998, 41. 1155-62], which enable us to establish structure and activity relationships (SAR). Among these analogs, we have discovered quite a few compounds possessing potent cytotoxicity, such as 3',6-disubstitued 2-phenyl-4-quinolones (A-1 ) etc [Li, L., Wang, H. K., Kuo, S. C, Wu, T. S., Lednicer, D., Lin, C. M., Hamel, E., Lee, K. H. Antitumor agents. 150.
2I,3',4',5I,5,6,7-substituted 2-phenyl-4- quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. 1994, 37, 1126-35]. However, most of the compounds with potent cytotoxicity were very lipophilic, and therefore, not suitable for in vivo and clinical studies. We thus made attempt to synthesize hydrophilic derivatives of these 2-aryl-4-quinolone skeletons in order to improve pharmacokinetic properties suitable for in vivo and clinical studies.
Figure imgf000005_0001
R6, R3'=F, Cl, OCH3
Summary of the Invention
Preferred embodiments of the present invention include (but not limited thereto) the following items:
1. A phosphate derivative of 2-aryl-4-quinolone having the following formulas Ia, Ib or Ic:
Figure imgf000005_0002
Figure imgf000006_0001
wherein
R2', R3', R41, Rs' and R6' independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
Figure imgf000006_0002
wherein n is an integer of 0-4, Y is 0 or S, X is F, Cl, or Br1 and R8 and R9 independently are H, (CH2)nYH, (CH2)nN(CnH2n+i)(CmH2m+1) or (CH2)nCH3, wherein n and Y are defined as above, and m is an integer of 0-4; R2, R3, R4 and R5 independently are H, (CH2)nCH3, (CH2)nYH,
Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
Figure imgf000006_0003
or R3 and R4 together is -Y(CH2)nY-, wherein n, Y, X, R8 and R9 are defined as above; and R1 and R1 1 independently are H, Li+, Na+, K+, N+R8R9R10Rn or benzyl wherein R10 and R11 independently are H, (CH2)nYH, (CH2)nN(CnH2n+1)(CmH2m+1) or (CH2)nCH3, n, m, R8 and R9 are defined as above.
2. The phosphate derivative according to Item 1 , which has the formula Ia.
3. The phosphate derivative according to Item 2, wherein R2', R3', R4", R5' and R6' are all H; or one of R2', R3', R4', Rs' and R6' is F, OCH3 or (CH2)HNR8Rg, and the others thereof are H, wherein n, R8 and Rg are defined as in Item 1.
4. The phosphate derivative according to Item 2, wherein R2, R3, R4, and R5 are all H; or one of R2, R3, R4, and R5 is F, OCH3, Y(CH2)nCH3 or (CH2JnNR8Rg, and the others thereof are H; or R2 and R5 are H, and R3 and R4 together is -O(CH2)nO-, wherein n, Y1 R8 and R9 are defined as in Item 1.
5. The phosphate derivative according to Item 2, wherein Ri and R1 1 are both H or both Na+. 6. The phosphate derivative according to Item 5, wherein R2 and R5 are H, and R3 and R4 together is -0(CH2)O-; and R2', R3', R4' and R5' are all H, and R6' is F.
7. The phosphate derivative according to Item 5, wherein R2 and R5 are H, and R3 and R4 together is -0(CH2)O-; and R2', R3', R4' and R6' are all H, and R5' is F.
8. The phosphate derivative according to Item 5, wherein R4 is F, and R2, R3 and R5 are H; and R2', R3', R4', R5' and R6'are all H.
9. The phosphate derivative according to Item 5, wherein R2, R3, R4 and R5 are all H; and R2', R3', R4', R5' and R6'are all H. 10. The phosphate derivative according to Item 5, wherein R4 is
OCH3, and R2, R3 and R5 are H; and R5' is F, and R2', R3', R4' and R6'are H.
11. The phosphate derivative according to Item 5, wherein R2 and R5 are H, and R3 and R4 together is -0(CH2)O-; and R2', R3', R4' and R6' are all H, and R5 1 is OCH3.
12. The phosphate derivative according to Item 5, wherein R4 is CH2N(C2H5)2, and R2, R3 and R5 are H; and R6' is F, and R2', R3', R4' and Rs'are H.
13. The phosphate derivative according to Item 5, wherein R4 is CH2N(C2H5)2, and R2, R3 and R5 are H; and R2', R3', R4', R5' and R6'are all H.
14. The phosphate derivative according to Item 5, wherein R4 is OCH3, and R2, R3 and R5 are H; and R5' is CH2N(C2Hs)2, and R2", R3 1, R4'
Figure imgf000008_0001
15. The phosphate derivative according to Item 1 , which has the formula Ib. 16. The phosphate derivative according to Item 15, wherein R2, R3,
R4, and R5 are all H; or one of R2, R3, R4 and R5 is F or OCH3, and the others thereof are H; or R2 and R5 are H, and R3 and R4 together is -0(CH2JnO-, wherein n is defined as in Item 1.
17. The phosphate derivative according to Item 15, wherein R2', R3' and R4' are all H; or one of R2', R3' and R4' is F or OCH3, and the others thereof are H.
18. The phosphate derivative according to Item 15, wherein Ri and R-i1 are benzyl.
19. The phosphate derivative according to Item 18, wherein R2 1, R3', R4', R2 and R5 are all H, and R3 and R4 together is -0(CH2)O-.
20. A pharmaceutical composition for the killing of solid cancer cells, which comprises a therapeutically effective amount of a phosphate derivative of 2-aryl-4-quinolone as set forth in any one of Item 1 to Item 19 or a pharmaceutically acceptable salt thereof, as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.
21. The pharmaceutical composition according to Item 20, wherein the solid cancer cells are human breast cancer, colon cancer, lung cancer, renal cancer, hepatoma, or leukemia cancer
22. The pharmaceutical composition according to Item 21 , wherein the solid cancer cells are human breast cancer or colon cancer.
23. A compound of 2-selenophene 4-quinolone having the following formulas Mb or Hc:
Figure imgf000009_0001
Mb Mc wherein
R2', R3' and R4' independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9l X, or (CH2)nNR8R9, wherein n is an integer of 0-4, Y is O or S, X is F, Cl, or Br, and Re and R9 independently are H, (CH2)nYH, (CH2)nN(CnH2n+i )(CmH2m+1 ) or (CH2)nCH3, wherein n and Y are defined as above, and m is an integer of 0-4; R2, R3, R4 and R5 independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
Figure imgf000009_0002
or R3 and R4 together is -Y(CH2JnY-, wherein n, Y, X, R8 and R9 are defined as above.
24. The compound according to Item 23, wherein R2, R3, R4, and R5 are all H; or one of R2, R3, R4 and R5 is F or OCH3, and the others thereof are H; or R2 and R5 are H, and R3 and R4 together is -O(CH2)nO-, wherein n is defined as in Item 19.
25. The compound according to Item 24, wherein R2', R3' and R4' are all H; or one of R2', R3' and R4' is F or OCH3, and the others thereof are H.
26. The compound according to Item 23 which has the formula Mb.
27. The compound according to Item 26, wherein R2', R3', R4', R2 and R5 are all H, and R3 and R4 together is -0(CH2)O-.
28. A pharmaceutical composition for the killing of solid cancer cells, which comprises a therapeutically effective amount of a compound of 2-selenophene 4-quinolone as set forth in any one of Item 23 to Item 27 or a pharmaceutically acceptable salt thereof, as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.
29. The pharmaceutical composition according to Item 28, wherein the solid cancer cells are human breast cancer, colon cancer, lung cancer, renal cancer, hepatoma, or leukemia cancer. 30. A compound of 2-phenyl-4-quinolone having the following formula
Ma:
Figure imgf000010_0001
Ma wherein
R2', R3', R4 1, R5' and R6' independently are H, (CH2)nCH3, (CH2)nYH,
Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
Figure imgf000010_0002
wherein n is an integer of 0-4, Y is O or S, X is F, Cl, or Br, and R8 and Rg independently are H, (CH2)nYH, (CH2)nN(CnH2n+1)(CmH2m+1) or (CH2)nCH3, wherein n and Y are defined as above, and m is an integer of 0-4; R2, R3, R4 and R5 independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
Figure imgf000011_0001
or R3 and R4 together is -Y(CH2)nY-, wherein n, Y1 X, R8 and R9 are defined as above; provided that one of R2, R3, R4 and R5 is (CH2)qNR8R9, or one of R2', R3', R4', R5' and R6' is (CH2)qNR8R9, wherein q is an integer of 1-4, and R8 and R9 are defined as above.
31. The compound according to Item 30, wherein R4 is CH2)qNR8R9, and R2, R3 and R5 are H, wherein q, R8 and Rg are defined as in Item 30.
32. The compound according to Item 30, wherein R5 1 is CH2)qNR8R9, and R2', R3', R4' and R6'are H, wherein q, R8 and R9 are defined as in Item
30.
33. The compound according to Item 31 , wherein R4 is CH2N(C2H5)2, R6' is F, and R2', R3', R4' and R5'are H.
34. The compound according to Item 31 , wherein R4 is CH2N(C2Hs)2, R2', R3', R4', R5' and R6'are all H.
35. The compound according to Item 32, wherein R4 is OCH3, and R2, R3 and R5 are H; and R5' is CH2N(C2Hs)2, and R2', R3', R4' and R6'are H.
36. A pharmaceutical composition for the killing of solid cancer cells, which comprises a therapeutically effective amount of a compound of 2-phenyl 4-quinolone as set forth in any one of Item 30 to Item 35 or a pharmaceutically acceptable salt thereof, as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.
37. The pharmaceutical composition according to Item 36, wherein the solid cancer cells are leukemia cancer. Brief Description of the Drawings
Fig. 1 shows effects of compound 1-1 and compound 1-1 -b on MCF7 tumor growth in a mouse xenograft model. Female SCID mice received injections of MCF7 transfectants to induce tumor xenografts. Mice were divided into five groups. The second to fifth groups were given i.p. with compounds 1-1 (15 mg/kg), 1-1 (30 mg/kg), 1-1 -b (22.5 mg/kg), and 1-1 -b (45 mg/kg), respectively, three times per week. Data are expressed as mean of tumor weights (g) ± S. E. M. * p < 0.05 compared with the control.
Fig. 2 shows effect of compound 1-1 -b on animal survival. BALB/c mice were intraperitoneal^ injected with CT-26 tumor cells for 7 days before beginning the treatments with compound 1-1 -b (5 mg/kg/day and 10 mg/kg/day QD x 7).
Fig. 3 shows effect of quinolone derivatives on the viability of human breast cancer cells. MCF7 cells were treated with DMSO (Control) or various concentrations (0.125 μM to 10 μM) of quinolone derivative for 48 hours and subsequent cell viability was measured by MTT assay. Results from three separate experiments were averaged and are presented as mean ± standard error as shown.
Detailed Description of the Invention
As shown in the following Examples 1 to 6, when 2-phenyl-4-quinolones (1-1 to I-6) was reacted with tetrabenzyl pyrophosphate in the presence of alkali, the corresponding phosphoric acid dibenzyl esters (1-1 -a to l-6-a) were obtained. Catalytic hydrogenation of compounds (1-1 -a to l-6-a) in alcohol affords the corresponding phosphoric acid mono esters(l-1 -b to l-6-b), which could be led to water soluble salts (1-1 -c to l-6-c).
Example 1
Figure imgf000013_0001
( I-l-c ) ( I-l-b )
Dibenzyl 2-(21-fluorophenyl)-6,7-methylenedioxyquinolin-4-yl-phosphate (1-1 -a)
Sodium hydride (13.7 mg, 0.57 mmol) was added at O0C to a stirred solution of compound 1-1 (64.5 mg, 0.23 mmol) in dry tetrahydrofuran (10 ml). After 1 h, tetrabenzyl pyrophosphate (100 mg, 0.19 mmol) was added and the stirring was continued for 20 min.
The mixture was filtered, and the filtrate was concentrated under vacuum at a temperature below 35CC. The residue was dissolved in dichloromethane, washed with an aqueous solution of sodium hydrogen carbonate, dried over MgSO4 and concentrated under vacuum to give compound 1-1 -a (69.1 mg, 67%) MP 101-104 0C
1H-NMR (CDCI3, 300 MHz): δ 8.01 -8.02 (m, 1 H1 H-5'), 7.77 (s, 1 H, H-5), 7.16-7.43 (m, 14H, H-3, H-3\ H-4', H-6\ Ph) , 7.05 (s, 1 H, H-8), 6.12
(s, 2H1 OCH2O), 5.26 (s, 2H, -CH2-Ph), 5.20 (s, 2H, -CH2-Ph) MS (m/z) 544 (ES+)
Anal, calcd for C30H25FNO6P: C, 66.30; H, 4.27; N, 2.58. Found: C, 66.28 ; H, 4.35; N, 2.55. 2-(2'-Fluorophenyl)-6,7-methylenedioxyquinolin-4-yl-phosphate (1-1 -b) A suspension of compound l-1 -a (97.7 mg, 0.18 mmol) in anhydrous
MeOH (10 ml) was submitted to hydrogenation in the presence of 10% Pd/C (50 mg) at room temperature for 10 min. The catalyst and precipitates was collected and dissolved in 10% NaHCO3 solution then filtered. The filtrate was acidified with dil HCI, the solid was then collected by filtration and washed with acetone to give compound 1-1 -b (63.5 mg, 97.2%). MP >300 0C 1H-NMR (DMSO-crø, 300 MHz): δ 7.93-7.98 (m, 1 H, H-5'), 7.74 (s, 1 H, H-5), 7.49-7.54 (m, 1 H, H-4'), 7.32-7.41 (m, 4H, H-3, H-8, H-3', H-6'), 6.22 (s, 2H, OCH2O). MS (m/z) 362 (ES-)
Anal, calcd for C16H13FNO6P: C, 52.91 ; H, 3.05; N, 3.86. Found: C, 52.73; H, 3.10; N, 3.81.
Sodium 2-(2'-fluorophenyl)-6,7-methylenedioxyquinolin-4-yl-phosphate (1-1 -c)
Compound 1-1 -b was added to a mixture of 20 ml Amberlite IR-120(Na+ form) and 20 ml water, and then stirred for 6h at room temperature. The mixture was then filtered to remove Amberlite, and then lyophilized to give 1-1 -c (49.1 mg, 69%).
1H-NMR (D2O, 200 MHz): δ 7.48-7.66 (m, 2H, H-4', H-6'), 7.40 (s, 1 H, H-8), 7.31-7.35 (m, 1 H, H-5), 7.1 1-7.19 (m, 2H, H-3', H-5'), 7.03 (s, 1 H, H-3), 5.92 (s, 2H, OCH2O). Example 2
Figure imgf000015_0001
H2, Pd/C MeOH
Amberhte IR- 120 (Na+)
Figure imgf000015_0002
Figure imgf000015_0003
( I-2-c ) ( I-2-b )
Dibenzyl 2-(3'-fluorophenyl)-6,7-methylenedioxyquinolin-4-yl-phosphate (I-2-a)
Sodium hydride (13.7 mg, 0.57 mmol) was added at O0C to a stirred solution of compound I-2 (64.5 mg, 0.23 mmol) in dry tetrahydrofuran (10 ml). After 1 h, tetrabenzyl pyrophosphate (100 mg, 0.19 mmol) was added and the stirring was continued for 20 min. The mixture was filtered, and the filtrate was concentrated under vacuum at a temperature below 35°C. The residue was dissolved in dichloromethane, washed with an aqueous solution of sodium hydrogen carbonate, dried over MgSO4 and concentrated under vacuum to give compound I-2-a (85.6 mg, 83 %). MP 94-96 0C
1H-NMR (DMSO-d6, 200 MHz): δ 7.61-7.78 (m, 2H1 H-2' , H-4'), 7.48-7.56 (m, 1 H, H-5'), 7.24-7.45 (m, 13H, H-5, H-8, H-6', Ph) , 7.10 (s, 1 H1 H-3), 6.21 (s, 2H1 OCH2O), 5.29 (s, 2H, -CH2-Ph), 5.24 (s, 2H, -CH2-Ph) MS (m/z) 544 (ES+) Anal, calcd for C30H25FNO6P: C, 66.30; H, 4.27; N, 2.58. Found: C, 66.25 ;
H, 4.34; N, 2.55.
2-(3'-Fluorophenyl)-6,7-methylenedioxyquinolin-4-yl-phosphate (l-2-b) A suspension of compound l-2-a (97.7 mg, 0.18 mmol) in anhydrous MeOH (10 ml) was submitted to hydrogenation in the presence of 10% Pd/C (50 mg) at room temperature for 10 min. The catalyst and precipitates was collected and dissolved in 10% NaHCO3 solution then filtered. The filtrate was acidified with dil HCI, the solid was then collected by filtration and washed with acetone to give compound l-2-b (60.8 mg, 93.1 %).
MP >300 0C
1H-NMR (DMSO-t/6, 200 MHz): δ 7.91 (s, 1 H, H-21), 7.87 (s, 1 H, H-4'), 7.83 (s, 1 H1 H-51), 7.50-7.62 (m, 2H, H-5, H-8), 7.25-7.36 (m, 2H, H-5', H-61), 6.24 (s, 2H1 OCH2O). MS (m/z) 362 (ES-)
Anal, calcd for C16H13FNO6P: C, 52.91 ; H, 3.05; N, 3.86. Found: C, 52.86; H, 3.12; N1 3.79.
Sodium 2-(3'-fluorophenyl)-6,7-methylenedioxyquinoline 4-yl-phosphate
(1-2-c) Compound l-2-b was added to a mixture of 20 ml Amberlite
IR-120(Na+ form) and 20 ml water, and then stirred for 6h at room temperature. The mixture was then filtered to remove Amberlite, and then lyophilized to give l-2-c (68.2 mg, 71 %).
1H-NMR (D2O, 200 MHz): δ 7.26-7.78 (m, 5H, H-5, H-8, H-21, H-5', H-6'), 6.90-6.96 (m, 2H, H-3, H-4'), 6.03 (s, 2H, OCH2O). Example 3
Figure imgf000017_0001
H2, Pd/C MeOH
Figure imgf000017_0002
Dibenzyl 6-fluoro-2-phenylquinolin-4-yl-phosphate (I-3-a)
Sodium hydride (13.7 mg, 0.57 mmol) was added at O0C to a stirred solution of compound I-3 (55.0 mg, 0.23 mmol) in dry tetrahydrofuran (10 ml). After 1 h, tetrabenzyl pyrophosphate (100 mg, 0.19 mmol) was added and the stirring was continued for 20 min.
The mixture was filtered, and the filtrate was concentrated under vacuum at a temperature below 35°C. The residue was dissolved in dichloromethane, washed with an aqueous solution of sodium hydrogen carbonate, dried over MgSO4 and concentrated under vacuum to give I-3-a as a colorless oil compound (84.4 mg, 89 %). 1H-NMR (DMSO-c/6, 200 MHz): δ 8.07-8.14 (m, 1 H, H-8), 7.92-7.97 (m,
2H, H-21 ,H-6'), 7.67-7.77 (m, 2H, H-3', H-51) , 7.40-7.50 (m, 1 OH, Ph), 5.31 (s, 2H, -CH1-Ph), 5.27(s, 2H, -CH2-Ph)
MS (m/z) 500 (ES+) Anal, calcd for C29H23FNO6P: C, 69.74; H1 4.64; N, 2.80. Found: C.69.75 ;
H, 4.60; N, 2.81. 6-Fluoro-2-phenylquinolin-4-yl-phosphate (I-3-b) A suspension of compound l-3-a (89.8 mg, 0.18 mmol) in anhydrous MeOH (10 ml) was submitted to hydrogenation in the presence of 10%
Pd/C (50 mg) at room temperature for 10 min. The catalyst and precipitates was collected and dissolved in 10% NaHCO3 solution then filtered. The filtrate was acidified with dil HCI, the solid was then collected by filtration and washed with acetone to give compound l-3-b. (50.5 mg, 88 %). MP >300 0C
1H-NMR (DMSO-dβ, 200 MHz): δ 8.07-8.14 (m, 3H, H-8, H-2', H-6'), 7.95 (s, 1 H, H-5), 7.70-7.74 {m, 2H, H-3\ H-5'), 7.50-7.56 (m, 3H, H-3, H-7,
H-41)
MS (m/z) 318 (ES-) Anal, calcd for C15H11FNO4P: C, 56.44; H, 3.47; N, 4.39. Found: C, 56.42;
H, 3.49; N, 4.30. Sodium 6-Fluoro-2-phenylquinolin-4-yl-phosphate (l-3-c)
Compound l-3-b was added to a mixture of 20 ml Amberlite IR-120(Na+ form) and 20 ml water, and then stirred for 6h at room temperature. The mixture was then filtered to remove Amberlite, and then lyophilized to give l-3-c (41.9 mg, 73%). 1H-NMR (D2O, 200 MHz): δ 7.20-7.83 (m, 5H, H-5, H-7, H-8, H-2', H-6'), 7.25-7.31 (m, 4H, H-3, H-31, H-4', H-5').
Example 4
Figure imgf000019_0001
H2, Pd/C MeOH
Amberlite IR- 120 (Na+)
Figure imgf000019_0002
Figure imgf000019_0003
( I-4-c ) ( I-4-b )
Dibenzyl 2-phenylquinolin-4-yl-phosphate (I-4-a)
Sodium hydride (13.7 mg, 0.57 mmol) was added at O0C to a stirred solution of compound I-4 (50.8 mg, 0.23 mmol) in dry tetrahydrofuran (10 ml). After 1 h, tetrabenzyl pyrophosphate (100 mg, 0.19 mmol) was added and the stirring was continued for 20 min.
The mixture was filtered, and the filtrate was concentrated under vacuum at a temperature below 35°C. The residue was dissolved in dichloromethane, washed with an aqueous solution of sodium hydrogen carbonate, dried over MgSO4 and concentrated under vacuum to give I-4-a as a colorless oil compound (71.3 mg, 78 %). 1H-NMR (DMSO-d6, 200 MHz): δ 8.05 (d, J= 8.2 Hz, 1 H, H-5), 7.73-7.98
(m, 5H, H-6, H-7, H-8, H-2' ,H-6'), 7.58 (of, J = 8.0Hz, 1 H, H-4'), 7.48-7.51 (m, 3H, H-3, H-3', H-5'), 7.29-7.40 (m, 1 OH, Ph), 5.31 (s, 2H,
-CH1-Ph), 5.27(s, 2H, -CH2-Ph) MS (m/z) 482 (ES+)
Anal, calcd for C29H24NO6P: C, 72.34; H, 5.02; N, 2.90. Found: C, 71.89 ; H, 5.13; N, 2.88. 2-Phenylquinolin-4-yl-phosphate (l-4-b)
A suspension of compound l-4-a (86.6 mg, 0.18 mmol) in anhydrous
MeOH (10 ml) was submitted to hydrogenation in the presence of 10% Pd/C (50 mg) at room temperature for 10 min. The catalyst and precipitates was collected and dissolved in 10% NaHCO3 solution then filtered. The filtrate was acidified with dil HCI, the solid was then collected by filtration and washed with acetone to give compound l-4-b (48.9 mg, 90.3 %). MP >300 0C 1H-NMR (DMSO-c/6, 200 MHz): δ 7.80-8.12 (m, 4H, H-5, H-8, H-2\ H-61), 7.49-7.78 (m, 6H, H-3, H-6, H-7, H-3\ H-4', H-51), 7.78 (s, 1 H, H-7), 7.66 (t, J = 8.0 Hz), 7.42-7.50 (m, 4H, H-3, H-31, H-41, H-51) MS (m/z) 300 (ES-)
Anal, calcd for C15H12NO6P: C, 59.81 ; H.4.02; N1 4.65. Found: C, 59.52; H, 4.13; N, 4.72.
Sodium 6-fluoro-2-phenylquinolin-4-yl-phosphate (l-4-c)
Compound l-4-b was added to a mixture of 20 ml Amberlite IR-120(Na+ form) and 20 ml water, and then stirred for 6h at room temperature. The mixture was then filtered to remove Amberlite, and then lyophilized to give l-4-c (41.2 mg, 74%).
1H-NMR (D2O, 200 MHz): δ 8.21 (of, J = 8.2 Hz, 1 H, H-5), 7.80-7.89 (m, 3H, H-8, H-2', H-61), 7.78 (s, 1 H, H-7), 7.66 (t, J = 8.0 Hz), 7.42-7.50 (m, 4H, H-3, H-31, H-4', H-5')
Example 5
Figure imgf000021_0001
H2, Pd/C MeOH
Figure imgf000021_0002
( I-5-b )
Dibenzyl 6-methoxy-2(3-'fluorophenyl)-quinolin-4-yl-phosphate (I-5-a) Sodium hydride (13.7 mg, 0.57 mmol) was added at O0C to a stirred solution of compound I-5 (61.9 mg, 0.23 mmol) in dry tetrahydrofuran (10 ml). After 1 h, tetrabenzyl pyrophosphate (100 mg, 0.19 mmol) was added and the stirring was continued for 20 min.
The mixture was filtered, and the filtrate was concentrated under vacuum at a temperature below 35°C. The residue was dissolved in dichloromethane, washed with an aqueous solution of sodium hydrogen carbonate, dried over MgSO4 and concentrated under vacuum to give I-5-a as a colorless oil compound (85.4 mg, 85 %)
1H-NMR (DMSO-c/6, 200 MHz): δ 7.98 (cf, J= 9.4 Hz, 1 H1 H-8), 7.74-7.83 (m, 3H, H-5, H-7, H-51), 7.43-7.54 (m, 1 H, H-6'), 7.41 -7.48 (m, 1 H,
H-2'), 7.20-7.22 (m, H-3), 5.31 (s, 2H, -CH1-Ph), 5.27(s, 2H, -CH1-Ph), 3.78 (s, 3H, OCH3). MS (m/z) 530 (ES+) Anal, calcd for C30H25FNO5P: C, 68.05; H, 4.76; N1 2.65. Found: C, 67.32 ;
H, 4.33; N1 2.78. 6-Methoxy-2(3-'fluorophenyl)-quinolin-4-yl-phosphate (l-5-b)
A suspension of compound l-5-a (95.2 mg, 0.18 mmol) in anhydrous MeOH (10 ml) was submitted to hydrogenation in the presence of 10% Pd/C (50 mg) at room temperature for 10 min. The catalyst and precipitates was collected and dissolved in 10% NaHCO3 solution then filtered. The filtrate was acidified with dil HCI, the solid was then collected by filtration and washed with acetone to give compound l-5-b (56.5 mg, 89.9 %).
MP >300 0C
1H-NMR (DMSO-c/6, 200 MHz): δ 7.93-7.89 (m, 4H1 H-5, H-7, H-8, H-51), 7.45-7.58 (m, 1 H, H-6'), 7.35-7.41 (m, 2H, H-2', H-4'), 7.20-7.32 (m, 1 H, H-3), 3.81 (s, 3H, OCH3) MS (m/z) 348 (ES-)
Anal, calcd for C16H13FNO5P: C1 55.02; H.3.75; N1 4.01. Found: C1 54.90; H1 3.89; N1 4.35.
Figure imgf000023_0001
H2, Pd/C MeOH
Amberlite IR- 120 (Na+)
Figure imgf000023_0002
Figure imgf000023_0003
( 1-6-c ) ( I-6-b)
Dibenzyl 2-(31-methoxyphenyl)-6>7-methylenedioxyquinolin-4-yl-phosphate (I-6-a)
Sodium hydride (13.7 mg, 0.57 mmol) was added at O0C to a stirred solution of compound I-6 (67.9 mg, 0.23 mmol) in dry tetrahydrofuran (10 ml). After 1 h, tetrabenzyl pyrophosphate (100 mg, 0.19 mmol) was added and the stirring was continued for 20 min. The mixture was filtered, and the filtrate was concentrated under vacuum at a temperature below 35°C. The residue was dissolved in dichloromethane, washed with an aqueous solution of sodium hydrogen carbonate, dried over MgSO4 and concentrated under vacuum to give to give I-6-a as a colorless oil compound (88.6 mg, 84 %) 1H-NMR (DMSO-dβ, 200 MHz): δ 7.60 (s, 1 H, H-6'), 7.55 (s, 1 H, H-2'), 7.25-7.40 (m, 14H1 H-5, H-8, H-41, H-5\ Ph), 6.21 (s, 2H, OCH2O), 5.28 (s, 2H1 -CtU-Ph), 5.24 (s, 2H, -CtU-Ph), 3.80 (s, 3H, OCH3) MS (m/z) 556 (ES+)
Anal, calcd for C3IH26NO7P: C1 67.02; H, 4.72; N, 2.52. Found: C.68.15 ; H, 4.68; N, 2.61. 2-(3'-Methoxyphenyl)-6,7-methylenedioxyquinolin-4-yl-phosphate (l-6-b) A suspension of compound l-6-a (97.74 mg, 0.18 mmol) in anhydrous
MeOH (10 ml) was submitted to hydrogenation in the presence of 10%
Pd/C (50 mg) at room temperature for 10 min. The catalyst and precipitates was collected and dissolved in 10% NaHCO3 solution then filtered. The filtrate was acidified with dil HCI, the solid was then collected by filtration and washed with acetone to give compound l-6-b(63.5 mg, 94
%).
MP >300 0C MS {m/z) 374 (ES-)
Anal, calcd for C17H14NO7P: C, 54.41 ; H, 3.76; N, 3.73. Found: C, 53.86; H, 3.66; N, 3.81.
Sodium 2-(3'-methoxyphenyl)-6,7-methylenedioxyquinolin-4-yl-phosphate
(l-6-c) Compound l-6-b was added to a mixture of 20 ml Amberlite
IR-120(Na+ form) and 20 ml water, and then stirred for 6h at room temperature. The mixture was then filtered to remove Amberlite, and then lyophilized to give l-6-c (53.9 mg, 76%).
1H-NMR (D2O, 200 MHz): δ 7.56 (s, 1 H, H-6'), 7.25-7.42 (m, 4H, H-5, H-8, H-2\ H-5'), 7.12 (s, 1 H, H-4'), 6.95 (s, 1 H, H-3), 6.00 (s, 2H, OCH2O), 3.62 (s, 3H, OCH3)
In the following Example 7, a novel intermediate, 2-selenophene 4-quinolone (l-7-d), was synthesized. 2-selenophene-4-quinolone (l-7-d) was reacted with tetrabenzyl pyrophosphate in the presence of alkali, the corresponding phosphoric acid dibenzyl ester (l-7-e) was obtained. Example 7
Figure imgf000025_0001
(I-7-a) (I-7-b)
Figure imgf000025_0002
( I-7-e )
Selenophene-2-carboxylic acid (I-7-a)
To a solution of selenophene (20 g, 152.7 mmol) in (Et)2O (150 ml) was added TMEDA (25.5 ml, 170.0 mmol) and n-butyllithium (66.1 ml of a 2.5 M solution in hexane, 152.8 mmol). The resulting solution was heated at reflux for 1.5 h, and then cooled in an acetone/CO2 bath, after which crushed solid carbon dioxide (4Og, 909.1 mmol) was added. The reaction mixture was allowed to return to room temperature, and quenched by addition of 10% KOH solution. The aqueous layer was acidified to pH 3 with 8 M HCI, extracted with (Et)2O, washed with brine, dried over MgSO4 filtered and concentrated under vacuum to give compound I-7-a ( 24.6 g, 92.1 %). MP 122-124 0C 1H-NMR (CDCI3-Cr1, 200 MHz): δ 8.92 (s, 1 H, -COOH), 8.37 (dd, J = 1.0 Hz, 5.6 Hz, 1 H, H-3), 8.13 (dd, J = 0.8 Hz, 3.8 Hz, 1 H, H-5), 7.37 (dd, J = 3.8 Hz, 5.6Hz, 1 H, H-4). MS (m/z) 175.0 (El+) Anal, calcd for C5H4O2Se: C, 34.31 ; H, 2.30. Found: C, 34.33 ; H, 2.28. N-(5-acetylbenzo[d][1 ,3]dioxol-6-yl)selenophene-2-carboxamide (l-7-c) l-7-a (2g, 11.40 mmol) was taken for subsequent chlorination by refluxing with thionyl chloride (4.1 ml, 56.18 mmol) for 2Oh to afford l-7-b, which, without further purification, was treated with
2-amino-(4,5-methylenedioxy)-acetophenone (1.63 g, 9.12 mmol) and triethylamine (2 ml, 14.80 mmol) in 100ml toluene, and refluxed for 3h. The reaction mixture was concentrated under vacuum, and the solid material is consecutively washed with ethanol and dried at 800C for 2h to give crude compound l-7-c (2.7 g, 74%). MP 198.5-198.8 0C
1H-NMR (DMSO-c/6, 200 MHz): δ 12.85 (s, 1 H, NHCO), 8.52 (d, J = 5.1 Hz, 1 H, H-3'), 8.16 (s, 1 H, H-4) , 7.93 (d, J = 3.8 Hz, 1 H, H-5'), 7.61 (s, 1 H, H-7) , 7.49-7.46 (m, 1 H, H-4'), 6.13 (s, 2H, OCH2O), 2.58 (s, 3H, CH3).
MS (m/z) 336.2 (El+)
Anal, calcd for C14H11 NO4Se: C, 50.01 ; H, 3.30; N, 4.17. Found: C,
50.11 ; H, 3.32; N, 4.15.
2-(2'-Selenophenyl)-6,7-(methylenedioxy)-4-quinolone (l-7-d) l-7-c (2.7 g, 8.0 mmol) was suspended in 100 ml f-BuOH. Potassium terf-butoxide (4.49 g, 40 mmol) was added, and the mixture was heated at reflux for 24 h. The mixture was cooled to room temperature, and poured onto 100 ml of aqueous NH4CI. The yellow-brown solid was collected and washed by distilled water to give compound l-7-d (3.1 g, 85 %). MP > 300 0C
1H-NMR (DMSO-d6, 200 MHz): δ 8.27 (s, 1 H, H-3'), 7.83 (s, 1 H, H-51), 7.39 (t, J = 4.5 Hz, 1 H, H-4') , 7.31 (s, 1 H, H-5), 7.14 (s, 1 H, H-8), 6.11 (s, 3H, H-3, OCH2O). MS (m/z) 318.2 (El+) Anal, calcd for C14H9NO3Se: C, 52.85; H, 2.85; N, 4.40. Found: C, 52.87; H, 2.82; N, 4.45. Dibenzyl 2-(2'-selenophenyl)-6,7-methylenedioxyquinolin-4-yl-phosphate (l-7-e)
Sodium hydride (30 mg, 1.25 mmol) was added at 00C to a stirred solution of compound l-7-d (100.0 mg, 0.32 mmol) in dry tetrahydrofuran (10 ml). After 1 h, tetrabenzyl pyrophosphate (204.6 mg, 0.38 mmol) was added and the stirring was continued for 20 min.
The mixture was filtered, and the filtrate was concentrated under vacuum at a temperature below 35°C. The residue was dissolved in dichloromethane, washed with an aqueous solution of sodium hydrogen carbonate, dried over MgSO4 and concentrated under vacuum to give the solid which was subjected to silica gel column chromatography. Elution with CH2Cb gave yellowish compound l-7-e (151.8 mg, 82 %). MP 110.5-110.8 0C
1H-NMR (DMSO-c/6, 200 MHz): δ 8.24 (d, J = 5.6 Hz, 1 H, H-3 ), 7.65 (d, J = 3.8 Hz, 1 H, H-5'), 7.57 (s, 1 H, H-5) , 7.05 (s, 1 H, H-8), 7.39-7.26 (m,
11 H, H-4', Ph ), 6.19 (s, 2H, OCH2O), 5.28 (s, 2H, -CH2-Ph), 5.24 (s, 2H1 -CH2-Ph). MS (m/z) 580 (ES+)
Anal, calcd for 2S0H22NO6PSe: C, 58.14; H, 3.83; N, 2.42. Found: C, 57.28; H, 3.56; N, 2.59.
Example 8
Figure imgf000028_0001
6-Methyl-2-phenylquinolin-4(1 H)-one (l-8-a)
A mixture of p-toluidine (2.14g , 0.02 mole), ethyl benzoylacetate (4.9g, 0.025 mole), and polyphosphoric acid (PPA) was heated at 1300C with stirring. After the reaction was complete, the mixture was cooled to room temperature and neutralized with 4 M NaOH. The yellow solid was filtered, washed with water, dried and recrystallized from ethanol to give compound l-8-a as white solid (2.9g, 48.9%). MP 290.2-291.5 0C
1H-NMR (DMSO-t/6, 200 MHz): δ 11.55 (1 H, s, H-1 ) , 7.88 (1 H, s, H-5) , 7.79-7.82 (2H, m, H-21, H-3') , 7.66 (1 H, d, J = 8.5 Hz, H-8) , 7.54-7.57 (3H, m, H-3', H-4', H-51) , 7.48 (1 H, d, J = 8.5 Hz, H-7) , 6.31 (1 H1 s, H-3), 2.40 (3H, s, CH3) MS (m/z) 235 (El+)
Anal. calcd for C16H13NO: C, 81.68; H, 5.57; N, 5.95. Found: C, 81.60; H, 5.63; N, 5.88.
4-(Benzyloxy)-6-methyl-2-phenylquinoline (I-8-b) l-8-a (700mg, 3mmole) was dissolved in dry DMF (30 ml), and NaH (360mg, 15 mmole) was added protionwise with stirring for 30 min at room temperature. Benzyl chloride (750mg, 6 mmole) was then added dropwise, and stirred at room temperature overnight. The reaction mixture was poured into ice-water and extracted with CH2CI2. The organic layer was washed with water, dried over MgSO4, and evaporated. The residue was further chromatographed over silica gel by elution with n-hexane-EtOAc (3:1 ), and recrystallized from /i-hexane-CH2CI2 to afford l-8-b as white crystal (536mg, 54.9%). MP 138.6-139.3 0C 1H-NMR (DMSO-dβ, 200 MHz): δ 8.23-8.26 (2H, m, H-2', H-6') ,
7.88-7.91 (2H, m, H-5, H-8) , 7.37-7.62 (9H, m, H-7, H-3', H-4\ H-5', Ph), 5.51 (2H, s, OCH2Ph), 2.48 (3H, s, CH3)
Anal, calcd for C23H19NO: C.84.89; H, 5.89; N, 4.30. Found: C, 84.93; H, 5.85; N, 4.33.
Λ/-{[4-(Benzyloxy)-2-phenylquinolin-6-yl]methyl}-Λ/-ethyl ethanamine (l-8-d) l-8-b (650mg, 2mmol), Λ/-bromo-succinimide (NBS1 360mg, 2 mmol), and 2,2'-azobis(isobutyronitrile) (AIBN, 30 mg, 0.19 mmol) were added to a dry round bottom flask, which was purged with argon. 50 ml of dry benzene was added to the reaction mixture in an argon atmosphere with stirring at room temperature for 30 min, and then refluxed at 800C for 1 h and then cooled to room temperature to give l-7-c, which, without further purification, was treated with diethylamine (3.0 ml, 29.0 mmole), and then refluxed for 1 h. After removing the solvent by evaporation, the mixture was partitioned with EtOAc and 50 ml 10% HCI., and then the acid layer was neutralized to PH 7-8 by 10% NaHCO3, extracted with EtOAc (100ml x 5). The organic layer was dried over MgSO4, and evaporated. The residue was further chromatographed over silica gel by elution with CH2CI2-methanol (3:1 ), and recrystallized from n-hexane-EtOAc to afford l-8-d as light-yellow solid (120mg, 15.1 %). MP 107.7-108.6 0C 1H-NMR (DMSO-c/6, 200 MHz): δ 8.22 (2H, m, H-2', H-6'), 8.01 (1 H, s, H-5) , 7.91 (1 H, d, H-8) , 7.33-7.69 (9H, m, H-7, H-3', H-4', H-5', Ph) , 5.49 (2H, s, OCH2Ph) , 3.65 (2H, s, CH1N(CH2CHa)2), 2.43(4H, q, J = 7 Hz, CH2N(CH2CH3)2), 0.93 (6H, t, J = 7 Hz1 CH2N(CH2CH3)2) MS (m/z) 396 (El+)
Anal, calcd for C27H28N2O: C.81.78; H, 7.12; N1 7.06. Found: C, 81.68; H, 7.03; N, 7.15.
6-[(Diethylamino)methyl]-2-phenylquinolin-4(1 /-/)-one (l-8-e) l-8-d (120mg, 0.3 mmol) was dissolved in glacial acetic acid (5 ml).
HBr (3ml) was added while the solution was heated to 600C, and the mixture was heated to 900C for 3h. After the reaction was complete, the reaction mixture was poured into water, and extracted with EtOAc. The acid layer was neutralized to pH 7-8 by adding 10% NaHCO3, and extracted with EtOAc (100ml x 5). The organic layer was dried over MgSO4, and evaporated. The residue was recrystallized from n-hexane-EtOAc to afford l-8-d as gray solid (55mg, 59.9%). MP 227.9-229.7 0C 1H-NMR (DMSO-c/6, 200 MHz): δ 7.96 (1 H, s, H-5), 7.78 (2H, m, H-2', H-61), 7.69 (1 H, d, H-8), 7.50-7.58 (4H, m, H-7, H-3', H-4', H-5'), 6.31
(1 H, s, H-3), 3.55 (2H, s, CH2N(CH2CHa)2), 2.41 (4H, q, J = 7 Hz, CH2N(CH2CHs)2), 0.92 (6H, t, J = 7 Hz, CH2N(CH2CH3)2) MS (m/z) 306 (El+) Anal, calcd for C20H22N2O: C, 78.40; H, 7.24; N, 9.14. Found: C, 78.43; H, 7.35; N, 9.08. Example 9
Figure imgf000031_0001
2-(2-Fluorophenyl)-6-methylquinolin-4(1 H)-one (l-9-a) A mixture of p-toluidine (2.14g , 0.02 mole), 2-fluoro-ethyl benzoylacetate (5.25g, 0.025 mole), and polyphosphoric acid (PPA) was heated at 13O0C with stirring. After the reaction was complete, the mixture was cooled to room temperature and neutralized with 4 M NaOH. The yellow solid was filtered, washed with water, dried and recrystallized from ethanol to give compound l-9-a as white solid (2.6g, 51.3%). MP 259.1-259.9 0C
1H-NMR (DMSO-c/6, 200 MHz): «57.86 (1 H, s, H-5), 7.64 (1 H, td, J = 7.58, H-4'), 7.47-7.57 (3H, m, H-7, H-8, H-6'), 7.30-7.43 (2H, d, J = 7.02, dd, J = 7.36, H-3', 5' ), 6.12 (1 H1 s, H-3), 2.36 (3H, s, CH3) MS (m/z) 253 (El+)
Anal, calcd for C16H22FNO: C, 75.88; H, 4.78; N, 5.53. Found: C, 75.94; H, 4.70; N, 5.46.
4-(Benzyloxy)-2-(2-fluorophenyl)-6-methylquinoline (I-9-b) l-9-a (750mg, 3mmole) was dissolved in dry DMF (30 ml), and NaH (360mg, 15 mmole) was added protionwise with stirring for 30 min at room temperature. Benzyl chloride (750mg, 6 mmole) was then added dropwise, and stirred at room temperature overnight. The reaction mixture was poured into ice-water and extracted with CH2Cb. The organic layer was washed with water, dried over MgSO4, and evaporated. The residue was further chromatographed over silica gel by elution with n-hexane-EtOAc (3:1 ), and recrystallized from n-hexane-CH2CI2 to afford l-9-b as white crystal (515mg, 50.0%). MP 91.5-92.8 0C 1H-NMR (DMSO-d6, 200 MHz): δ 7.84-7.97 (3H, m, H-5, H-8, H-41) , 7.26-7.58 (10H, m, H-3, H-7, H-3', H-5',H-6\ Ph) , 5.38 (2H, s, OCH2Ph), 2.45 (3H, s, CH3) MS (m/z) 343 (El+)
Anal, calcd for C23H18FNO: C, 80.45; H, 5.28; N, 4.08. Found: C, 80.51 ; H, 5.29; N, 4.17.
Λ/-{[4-(Benzyloxy)-2-(2-fluorophenyl)quinolin-6-yl]methyl}-Λ/- ethylethanamine (l-9-d) l-9-b (680mg, 2mmol), Λ/-bromo-succinimide (NBS, 360mg, 2 mmol), and 2,2'-azobis(isobutyronitrile) (AIBN, 30 mg, 0.19 mmol) were added to a dry round bottom flask, which was purged with argon. 50 ml of dry benzene was added to the reaction mixture in an argon atmosphere with stirring at room temperature for 30 min, and then refluxed at 80°C for 1 h and then cooled to room temperature to give l-9-c, which, without further purification, was treated with diethylamine (3.0 ml, 29.0 mmole), and then refluxed for 1 h. After removing the solvent by evaporation, the mixture was partitioned with EtOAc and 50 ml 10% HCI., and then the acid layer was neutralized to PH 7-8 by 10% NaHCO3, extracted with EtOAc (100ml x 5). The organic layer was dried over MgSO4, and evaporated. The residue was further chromatographed over silica gel by elution with
CH2Cl2-methanol (3:1 ), and recrystallized from n-hexane-EtOAc to afford l-9-d as yellow solid (120mg, 15.1 %). MP 51.2-51.5 °C
1H-NMR (DMSO-c/6, 200 MHz): δ 8.04 (1 H, s, H-5) , 7.84-7.96 (2H1 m, H-8, H-5') , 7.69 (1 H, dd, H-4') , 7.28-7.54 (9H1 m, H-3, H-7, H-3', H-6', Ph) , 5.41 (2H, s, OCHsPh) , 3.68 (2H, s, CHsN(CH2CHa)2) , 2.46 (4H, q, J = 7, CH2N(CH2CHa)2), 0.94 (6H, t, J = 7, CH2N(CH2CH3)S)
MS (m/z) 414 (El+)
Anal, calcd for C27H27FN2O: C, 78.23; H, 6.57; N1 6.76. Found: C, 78.25; H, 6.67; N, 6.74.
6-[(Diethylamino)methyl]-2-(2-fluorophenyl)quinolin-4(1 /-/)-one (l-9-e) l-9-d (120mg, 0.3 mmol) was dissolved in glacial acetic acid (5 ml). HBr (3ml) was added while the solution was heated to 600C, and the mixture was heated to 900C for 3h. After the reaction was complete, the reaction mixture was poured into water, and extracted with EtOAc. The acid layer was neutralized to pH 7-8 by adding 10% NaHCO3, and extracted with EtOAc (100ml x 5). The organic layer was dried over MgSO4, and evaporated. The residue was recrystallized from n-hexane-EtOAc to afford l-8-e as gray solid (58mg, 59.6%). MP 184.2-184.7 0C 1H-NMR (DMSO-dβ, 200 MHz): ό 11.9 (1 H, s, H-1 ), 7.97 (1 H, s, H-5),
7.52-7.69 (4H, m, H-7, H-8, H-4', H-6'), 7.31-7.43 (2H, m, H-3', H-5') , 6.12 (1 H, s, H-3) , 3.57 (2H, s, CH2N(CH2CH3)2) , 2.40 (4H, q, J = 7 Hz, CH2N(CH2CHa)2), 0.92 (6H, t, J = 7 Hz, CH2N(CH2CHa)2) MS (m/z) 324 (El+) Anal, calcd for C20H21 FN2O: C, 74.05; H, 6.53; N, 8.64. Found: C, 73.94; H, 6.62; N, 8.67. Example 10
Figure imgf000034_0001
( I-10-a )
Figure imgf000034_0002
diethylamine benzene reflux
Figure imgf000034_0003
( I-10-d )
Figure imgf000034_0004
( I-10-e ) ( I-10-f)
Ethyl 3-methyl-benzoyl-acetate (1 -10-a)
To a vigorously stirred suspension of NaH (564 mg, 48.5 mmol) and CO(OEt)2 (5.73 g, 48.5 mmol) in anhydrous toluene (50ml) was added dropwise a solution of 3-methylacetophenone (4.33 g, 32.3 mmole) in toluene under reflux. The mixture was allowed to reflux and was stirred for 30 min after the addition was complete. When cooled to room temperature, the mixture was acidified with glacial AcOH. After ice-cold water was added, the mixture was extracted with toluene. The organic layer was dried over MgSO4, and evaporated. The residue was further chromatographed over silica gel by elution with CH2CI2-/i-haxane (3:2) to afford l-10-b as light-yellow liquid (3.13g, 46.9%) 1H-NMR (DMSO-t/6, 200 MHz): δ 7.68-7.72 (2H, m, H-4, H-6) , 7.32-7.36 (2H, m, H-2, H-3) , 4.16 (2H, q, J = 7, CH2CH3) , 3.94 (2H, s, H-10) , 2.38 (3H, s, CH3), 1.2 (3H, t, J = 7,CH2CHa) MS (m/z) 206 (El+) Anal, calcd for C12H14O3: C, 69.88; H, 6.84; Found: C, 69.72; H, 6.95.
6-Methoxy-2-m-tolylquinolin-4(1 H)-one (l-10-b)
A mixture of p-anisidine (2.14g , 0.02 mole), l-10-a (5.1 g, 0.025 mole), and polyphosphoric acid (PPA) was heated at 1300C with stirring. After the reaction was complete, the mixture was cooled to room temperature and neutralized with 4 M NaOH. The yellow solid was filtered, washed with water, dried and recrystallized from ethanol to give compound l-9-a as light-purple solid (2.6g, 25.8%). MP 262.2-264.1 0C 1H-NMR (DMSO-c/6, 200 MHz): δ 7.70 (1 H, d, H-8), 7.55-7.60 (2H, m, H-5, 7) , 7.25-7.47 (4H, m, H-2', H-4', H-5', H-6') , 6.33 (1 H, s, H-3) , 3.80 (3H, s, OCH3), 2.37 (3H, s, CH3) MS (m/z) 265 (El+)
Anal, calcd for C17H15NO: C, 76.79; H, 5.70; N, 5.28. Found: C, 76.81 ; H, 5.62; N, 5.34.
4-(Benzyloxy)-6-methoxy-2-m-tolylquinoline (1-10-c) l-10-b (795mg, 3mmole) was dissolved in dry DMF (30 ml), and NaH (360mg, 15 mmole) was added protionwise with stirring for 30 min at room temperature. Benzyl chloride (750mg, 6 mmole) was then added dropwise, and stirred at room temperature overnight. The reaction mixture was poured into ice-water and extracted with CH2CI2. The organic layer was washed with water, dried over MgSO4, and evaporated. The residue was further chromatographed over silica gel by elution with /7-hexane-EtOAc (3:1 ), and recrystallized from n-hexane-CH2CI2 to afford 1-10-c as white crystal (530mg, 49.7%). MP 133.0-134 0C 1H-NMR (DMSO-d6, 200 MHz): δ 8.00 (1 H, s, H-5), 7.96 (1 H, d, H-8), 7.89 (1 H, d, J = 8 Hz, H-7), 7.32-7.58 (6H1 m, H-3, H-2', H-5', H-6\ Ph), 7.22 (1 H, d, J = 7 Hz, H-4'), 5.50 (2H, s, OCH2Ph), 3.83 (3H, s, OCH3), <52.38 (3H, s, CH3) MS (m/z) 355 (El+)
Anal, calcd for C24H21 NO2: C, 81.10; H, 5.96; N, 3.94. Found: C, 81.9; H, 5.81 ; N, 3.97.
Λ/-{[3-(4-(Benzyloxy)-6-methoxyquinolin-2-yl)phenyl)methyl}-Λ/-ethylethanamine (l-10-e)
1-10-c (530mg, 2mmol), Λ/-bromo-succinimide (NBS, 360mg, 2 mmol), and 2,2'-azobis(isobutyronitrile) (AIBN, 30 mg, 0.19 mmol) were added to a dry round bottom flask, which was purged with argon. 50 ml of dry benzene was added to the reaction mixture in an argon atmosphere with stirring at room temperature for 30 min, and then refluxed at 800C for 1 h and then cooled to room temperature to give 1-10-d, which, without further purification, was treated with diethylamine (3.0 ml, 29.0 mmole), and then refluxed for 1 h. After removing the solvent by evaporation, the mixture was partitioned with EtOAc and 50 ml 10% HCI., and then the acid layer was neutralized to PH 7-8 by 10% NaHCO3, extracted with EtOAc (100ml x 5). The organic layer was dried over MgSO4, and evaporated. The residue was further chromatographed over silica gel by elution with CH2CI2-methanol (3:1 ), and recrystallized from n-hexane-EtOAc to afford l-10-e as yellow solid (25mg, 2.9%). MP 89.2-89.5 0C
1H-NMR (DMSO-dβ, 200 MHz): δ 8.13 (1 H, s, H-3). 7.87-8.04 (2H, m, H-7, 8), 7.34-7.43 (10H, m, H-3, H-2', H-4', H-5', H-6', Ph), 5.51 (2H, s, OCH2Ph), 3.84 (3H, s, OCH3), 3.69 (2H, s, CH2N(CH2CH3)2), 2.53 (4H, q, J = 7 Hz, CH2N(CH2CHa)2), 0.99 (6H, t, J = 7 Hz, CH2N(CH2CH3)S) MS (m/z) 426 (El+)
Anal, calcd for C28H30N2O2: C, 78.83; H, 7.90; N, 6.57. Found: C, 78.95; H, 7.14; N, 6.48. 2-{3-[(Diethylamino)methyl]phenyl}-6-methoxyquinolin-4(1 H)-one (1-10-f) l-10-e (42mg, 0.1 mmol) was dissolved in glacial acetic acid (5 ml). HBr (3ml) was added while the solution was heated to 600C, and the mixture was heated to 900C for 3h. After the reaction was complete, the reaction mixture was poured into water, and extracted with EtOAc. The acid layer was neutralized to pH 7-8 by adding 10% NaHCO3, and extracted with EtOAc (100ml x 5). The organic layer was dried over MgSO4, and evaporated. The residue was recrystallized from n-hexane-EtOAc to afford l-10-f as gray solid (20.8mg, 61.9%). MP 152.1-152.7 0C
1H-NMR (DMSO-c/6, 200 MHz): δ 11.76 (1 H, s, H-1 ), 7.67-7.74 (3H, m, H-5, H-8, H-6'), 7.46-7.49 (3H, m, H-7, H-2\ H-4'), 7.27 (1 H, dd, H-5')' , 6.27 (1 H1 s, H-3) , 3.80 (3H, s, OCH3) , 3.67 (2H, s, CH1N(CH2CHa)2) , 2.53 (4H, q, J = 7 Hz, CH2N(CH2CHs)2), 0.97 (6H, t, J = 7 Hz,
CH2N(CH2CH3)2).
Anal, calcd for C21 H24N2O2: C.74.97; H, 7.19; N, 8.33. Found: C, 74.81 ; H, 7.33; N, 8.31.
Anti cancer activities
Effects of compounds 1-1 and 1-1 -b on anti-tumor activity in vivo
(I) Effects of compounds 1-1 and 1-1 -b on MCF-7 tumor xenograft model 1-1 Materials and Methods
Female GALB/cAnN-Foxn1.E SCID mice (18-20 g; 6-8 weeks of age) were purchased from the National Animal Center and maintained in pressurized ventilated cage according to institutional regulations. The mice were implanted subcutaneously with estradiol (0.7mg) 2 days before tumor transplantation. MCF-7 cells (2 χ106) were inoculated s.c. into the right flank of the mice. After appearance of a 150-mm3 tumor nodule, 30 tumor-bearing mice were randomly divided into five groups for treatment with vehicle (PBS), 1-1 or 1-1 -b. The first groups only received vehicle. The second to fifth groups were given i.p. the following treatments three times per week, respectively: 1-1 (15 mg/kg), 1-1 (30 mg/kg), l-1-b (22.5 mg/kg), and l-1 -b (45 mg/kg). Mice were weighed and tumors were measured using calipers every week. Tumor size was calculated with the following formula: (L + W) / 2, where L is the length and W is the width. On the final day of the treatment, mice were sacrificed; tumors were excised, weighted, and sectioned; and the tumor sections were embedded in OCT compound and frozen at -700C. I-2 Results
The effects of 1-1 or l-1 -b, were examined in vivo. Thirty female SCID mice were individually injected s.c. with MCF7 cells. The mice were divided into five groups (six mice per group) and treated with vehicle alone, 1-1 (15 or 30 mg/kg), 1-1 -b (22.5 or 45 mg/kg). As shown in Fig. 1 , this in vivo tumor model shows a significant reduction in tumor volume in mice treated with 45 mg/kg l-1 -b when compared with control mice (P < 0.001 ). These results demonstrate that l-1 -b significantly inhibited MCF7 tumor growth in a mouse xenograft model.
(II) Effects of compounds 1-1 and l-1-b on CT-26 intraperitoneal tumor model 11-1 Materials and Methods
30 male 6-week-old Balb/c mice, were purchased from the National Animal cancer and maintained in pressurized ventilated cage according to institutional regulations. CT-26 (1 *106) cells were injected into peritoneal cavities at day 0. Animals were randomly assigned to anti-tumoral efficacy study (n=10). Seven days after tumor inoculation, oral administration of 5 and 10 mg/kg of 1-1 -b (QD for seven times) to the mice was carried out. The survival rate and body weight of the animals was monitored. II-2 Results 11-2-1 Appearance of mice after treatment
Mice in the excipient control group showed overt ascites, while mice receiving orally 1-1 -b (5 mg/kg/day, QD x 7) and 1-1 -b (10 mg/kg/day, QD x 7) exhibited reduced ascites development. II-2-2 The average life span of mice after treatment As shown in Fig. 2, all mice in the excipient control group were dead
40 days after, while those receiving compounds 1-1 -b (5 mg/kg/day, QD x 7) and compounds 1-1 -b (10 mg/kg/day, QD x 7) were all dead respectively by day 45 and day 50 post challenge. The average life span was prolonged by 140% at the dose of (10 mg/kg/day, QD x 7) and by 120% at the dose of (5 mg/kg/day, QD x 7). A maximally tolerated dose was not achieved.
Cell viability assay (MTT Assay)
Cells were seeded in a 24-well microtiter plate (2 " 104 cells/well) overnight, then treated with DMSO (Control) or various concentrations of test compounds, and incubated for 48 hours. The effect of test compounds on cell growth was examined by the MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.
Briefly, 40 μ\ of MTT solution (2 mg/ml, Sigma Chemical Co.) was added to each well to make a final volume of 500 μ\ and incubated for 1 h at
370C. The supernatant was aspirated, and the MTT-formazan crystals formed by metabolically viable cells were dissolved in 200 μ\ of DMSO. Finally, the absorbance at O. D. 550 nm was detected by enzyme-linked immunosorbent assay (ELISA) reader. Results: Cytotoxic effect of compounds 1-1 -b, l-2-b, l-3-b, l-4-b, l-5-b, l-7-d, l-7-e against the human breast cancer MCF-7 cells
The cytotoxic effect of compounds 1-1 -b, l-2-b, l-3-b, l-4-b, l-5-b, l-7-d, l-7-e were evaluated in the human breast cancer MCF-7 cells. As shown in Fig. 3, treatment with 0.125 to 10 μM of these compounds caused a dose-dependent decrease of cell viability. These results indicate that compounds 1-1 -b, l-2-b, l-3-b, l-4-b, l-5-b, l-7-d, l-7-e show significant cytotoxicity against MCF-7 cells. Therefore, these new derivatives of 2-aryl-quinolines are proposed as potential therapeutic agents for the treatment of cancers. Cytotoxic activity of compound l-7-d
In vitro cytotoxic activity of compound l-7-d was tested in HCT-116, Hep G2, NCI-H226, A549, A498 and HL-60 cells. As shown in Table 1 , compound l-7-d demonstrates significant inhibition against most of the six cancer cell lines and most notably, is quite active against HCT-116 and HL-60 cells. Compound l-7-d shows an IC50 of 0.9 μM against HCT-116 and an IC50 of 0.5 μM against HL-60 cell. Compound l-7-d is an attractive candidate for development as a novel anti-cancer agent.
Table 1
Figure imgf000040_0001
* Six cancer cell lines were treated with compound l-7-d for 48h. After treatment, cells were harvested and examined using MTT assay. * IC50 value means the concentration causing 50% growth-inhibitory effect. * HCT-116, colon cancer cell line; Hep G2, hepatoma cancer cell line; NCI-H226, non-small cell lung cancer cell line; A549, lung cancer cell line; A498, renal cancer cell line; HL-60, leukemia cancer cell line.
Cytotoxic activity of compound l-8-e, l-9-e and 1-10-f
In vitro cytotoxic activity of compound l-8-e, l-9-e and 1-10-f were tested in HL-60 cells. As shown in Table 2, compound l-8-e and l-9-e demonstrated significant inhibition against HL-60 cancer cell lines. Compound l-8-e showed an IC50 of 15 μM and compound l-9-e showed an IC50 of 5.8 μM against HL-60 cell. Compound l-9-e is an attractive candidate for development as a novel anti-cancer agent.
Table 2
Figure imgf000041_0001
* HL-60 cell were treated with compound l-8-e, l-9-e and I-10-f for 48h. After treatment, cells were harvested and examined using MTT assay.
* IC50 value means the concentration causing 50% growth-inhibitory effect.
* HL-60, leukemia cancer cell line.

Claims

What Is Claimed Is:
1. A phosphate derivative of 2-aryl-4-quinolone having the following formulas Ia, Ib or Ic:
Figure imgf000042_0001
wherein
R2', Rs', R4', R5' and R6 1 independently are H, (CH2)nCH3) (CH2)nYH, Y(CH2)nCH3l Y(CH2)nYH, Y(CH2)nNR8R9) X, (CH2)nNR8R9,
Figure imgf000042_0002
wherein n is an integer of 0-4, Y is O or S, X is F, Cl, or Br, and R8 and R9 independently are H, (CH2)nYH, (CH2)nN(CnH2n+1)(CmH2m+i) or (CH2)nCH3, wherein n and Y are defined as above, and m is an integer of 0-4; R2, R3, R4 and R5 independently are H, (CH2)nCH3) (CH2)nYH,
Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9)
Figure imgf000043_0001
or R3 and R4 together is -Y(CH2)nY-, wherein n, Y, X, R8 and R9 are defined as above; and
R1 and R1' independently are H, Li+, Na+, K+, N+R8RgRiORn or benzyl wherein R10 and R1I independently are H, (CH2)nYH,
(CH2)nN(CnH2n+i)(CmH2m+i) or (CH2)nCH3, n, m, R8 and R9 are defined as above.
2. The phosphate derivative according to claim 1 , which has the formula Ia.
3. The phosphate derivative according to claim 2, wherein R2', R3', R4', R5' and R6' are all H; or one of R2', R3', FV, Rs' and R6' is F, OCH3 or (CH2JnNR8R9, and the others thereof are H, wherein n, R8 and R9 are defined as in claim 1.
4. The phosphate derivative according to claim 2, wherein R2, R3, R4, and R5 are all H; or one of R2, R3, R4, and R5 is F, OCH3, Y(CH2)nCH3 or (CH2JnNR8Rg, and the others thereof are H; or R2 and R5 are H, and R3 and R4 together is -O(CH2)nO-, wherein n, Y, R8 and R9 are defined as in claim 1.
5. The phosphate derivative according to claim 2, wherein R1 and R1' are both H or both Na+.
6. The phosphate derivative according to claim 5, wherein R2 and R5 are H, and R3 and R4 together is -0(CH2)O-; and R2', R3', R4' and R5' are all H, and R6' is F.
7. The phosphate derivative according to claim 5, wherein R2 and R5 are H, and R3 and R4 together is -0(CH2)O-; and R2', R3', R4 1 and R6' are all H, and R5' is F.
8. The phosphate derivative according to claim 5, wherein R4 is F, and R2, R3 and R5 are H; and R2', R3', R4', R5' and R6'are all H.
9. The phosphate derivative according to claim 5, wherein R2, R3, R4 and R5 are all H; and R2', R3', R4', R5 1 and R6'are all H.
10. The phosphate derivative according to claim 5, wherein R4 is
OCH3, and R2, R3 and R5 are H; and R5' is F, and R2', R3', R4' and R6'are H.
11. The phosphate derivative according to claim 5, wherein R2 and R5 are H, and R3 and R4 together is -0(CH2)O-; and R2', R3', R4' and R6' are all H, and R5' is OCH3.
12. The phosphate derivative according to claim 5, wherein R4 is CH2N(C2Hs)2, and R2, R3 and R5 are H; and R6' is F, and R2', R3', R4' and Rs'are H.
13. The phosphate derivative according to claim 5, wherein R4 is CH2N(C2H5)2, and R2, R3 and R5 are H; and R2', R3', RV, R5' and R6'are all H.
14. The phosphate derivative according to claim 5, wherein R4 is OCH3, and R2, R3 and R5 are H; and R5' is CH2N(C2Hs)2, and R2 1, R3', R4' and R6'are H.
15. The phosphate derivative according to claim 1 , which has the formula Ib.
16. The phosphate derivative according to claim 15, wherein R2, R3, R4, and R5 are all H; or one of R2, R3. R4 and R5 is F or OCH3, and the others thereof are H; or R2 and R5 are H, and R3 and R4 together is -O(CH2)nO-, wherein n is defined as in claim 1.
17. The phosphate derivative according to claim 15, wherein R2', R3' and R4' are all H; or one of R2', R3' and R4' is F or OCH3, and the others thereof are H.
18. The phosphate derivative according to claim 15, wherein R1 and
R1 1 are benzyl.
19. The phosphate derivative according to claim 18, wherein R2', R3', R4', R2 and R5 are all H, and R3 and R4 together is -0(CH2)O-.
20. A pharmaceutical composition for the killing of solid cancer cells, which comprises a therapeutically effective amount of a phosphate derivative of 2-aryl-4-quinolone as set forth in any one of claim 1 to claim 19 or a pharmaceutically acceptable salt thereof, as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.
21. The pharmaceutical composition according to claim 20, wherein the solid cancer cells are human breast cancer, colon cancer, lung cancer, renal cancer, hepatoma, or leukemia cancer
22. The pharmaceutical composition according to claim 21 , wherein the solid cancer cells are human breast cancer or colon cancer.
23. A compound of 2-selenophene 4-quinolone having the following formulas Hb or Mc:
Figure imgf000046_0001
wherein
R2', R3' and R4' independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, or (CH2)nNR8R9, wherein n is an integer of 0-4, Y is O or S, X is F, Cl, or Br, and Re and R9 independently are H, (CH2)nYH, (CH2)nN(CnH2n+i)(CmH2m+1 ) or (CH2)nCH3, wherein n and Y are defined as above, and m is an integer of 0-4;
R2, R3, R4 and R5 independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
Figure imgf000046_0002
or R3 and R4 together is -Y(CH2)nY-, wherein n, Y, X, R8 and R9 are defined as above.
24. The compound according to claim 23, wherein R2, R3, R4, and R5 are all H; or one of R2, R3, R4 and R5 is F or OCH3, and the others thereof are H; or R2 and R5 are H, and R3 and R4 together is -O(CH2)nO-, wherein n is defined as in claim 19.
25. The compound according to claim 24, wherein R2', R3' and R4' are all H; or one of R2', R3' and R4' is F or OCH3, and the others thereof are H.
26. The compound according to claim 23 which has the formula Mb.
27. The compound according to claim 26, wherein R2', R3', R4', R2 and R5 are all H, and R3 and R4 together is -0(CH2)O-.
28. A pharmaceutical composition for the killing of solid cancer cells, which comprises a therapeutically effective amount of a compound of 2-selenophene 4-quinolone as set forth in any one of claim 23 to claim 27 or a pharmaceutically acceptable salt thereof, as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.
29. The pharmaceutical composition according to claim 28, wherein the solid cancer cells are human breast cancer, colon cancer, lung cancer, renal cancer, hepatoma, or leukemia cancer.
30. A compound of 2-phenyl-4-quinolone having the following formula
Ma:
Figure imgf000047_0001
Ma wherein R2', R3', R4', R5' and R6' independently are H, (CH2)nCH3, (CH2)nYH,
Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9, X, (CH2)nNR8R9,
Figure imgf000048_0001
wherein n is an integer of 0-4, Y is O or S, X is F, Cl, or Br, and R8 and R9 independently are H, (CH2)nYH, (CH2)nN(CnH2n+1)(CmH2m+1 ) or (CH2)nCH3, wherein n and Y are defined as above, and m is an integer of 0-4; R2, R3, R4 and R5 independently are H, (CH2)nCH3, (CH2)nYH, Y(CH2)nCH3, Y(CH2)nYH, Y(CH2)nNR8R9) X, (CH2)nNR8R9,
Figure imgf000048_0002
or R3 and R4 together is -Y(CH2)nY-, wherein n, Y, X, R8 and R9 are defined as above; provided that one of R2, R3, R4 and R5 is (CH2)qNR8R9, or one of R2',
R3', R4', R5' and Re' is (CH2)qNR8R9, wherein q is an integer of 1 -4, and R8 and Rg are defined as above.
31 . The compound according to claim 30, wherein R4 is CH2)qNR8R9, and R2, R3 and R5 are H, wherein q, R8 and R9 are defined as in claim 30.
32. The compound according to claim 30, wherein R5 1 is CH2)qNR8R9, and R2', R3', R4' and R6'are H, wherein q, R8 and R9 are defined as in claim 30.
33. The compound according to claim 31 , wherein R4 is CH2N(C2H5)2, R6' is F, and R2', R3', R4' and R5'are H.
34. The compound according to claim 31 , wherein R4 is CH2N(C2H5)2, R2', R3', R4', R5' and R6'are all H.
35. The compound according to claim 32, wherein R4 is OCH3, and R2, R3 and R5 are H; and R5' is CH2N(C2Hs)2, and R2', R3', R4' and R6'are H.
36. A pharmaceutical composition for the killing of solid cancer cells, which comprises a therapeutically effective amount of a compound of 2-phenyl 4-quinolone as set forth in any one of claim 30 to claim 35 or a pharmaceutically acceptable salt thereof, as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient, wherein the solid cancer cells comprise human breast cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, stomach cancer, prostate cancer, ileocecal carcinoma, glioblastoma, bone cancer, epidermoid carcinoma of the nasopharynx, hepatoma or leukemia cancer.
37. The pharmaceutical composition according to claim 36, wherein the solid cancer cells are leukemia cancer.
PCT/US2007/025056 2006-12-07 2007-12-07 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents WO2008070176A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2670292A CA2670292C (en) 2006-12-07 2007-12-07 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
NZ577130A NZ577130A (en) 2006-12-07 2007-12-07 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
US12/448,088 US8440692B2 (en) 2006-12-07 2007-12-07 Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
KR1020097014196A KR101139413B1 (en) 2006-12-07 2007-12-07 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
CN2007800447969A CN101583280B (en) 2006-12-07 2007-12-07 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
EP07853279A EP2096924B1 (en) 2006-12-07 2007-12-07 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
AU2007328034A AU2007328034B2 (en) 2006-12-07 2007-12-07 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
JP2009540310A JP5102843B2 (en) 2006-12-07 2007-12-07 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
US13/892,576 US9023867B2 (en) 2006-12-07 2013-05-13 Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents
US13/892,545 US9029394B2 (en) 2006-12-07 2013-05-13 2-phenyl-4-quinolones as anticancer agents
US13/892,522 US9023866B2 (en) 2006-12-07 2013-05-13 2-selenophene-4-quinolones as anticancer agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87325806P 2006-12-07 2006-12-07
US60/873,258 2006-12-07

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US12/448,088 A-371-Of-International US8440692B2 (en) 2006-12-07 2007-12-07 Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
US13/892,545 Division US9029394B2 (en) 2006-12-07 2013-05-13 2-phenyl-4-quinolones as anticancer agents
US13/892,522 Division US9023866B2 (en) 2006-12-07 2013-05-13 2-selenophene-4-quinolones as anticancer agents
US13/892,576 Division US9023867B2 (en) 2006-12-07 2013-05-13 Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents

Publications (1)

Publication Number Publication Date
WO2008070176A1 true WO2008070176A1 (en) 2008-06-12

Family

ID=39492568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/025056 WO2008070176A1 (en) 2006-12-07 2007-12-07 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents

Country Status (11)

Country Link
US (4) US8440692B2 (en)
EP (3) EP2096924B1 (en)
JP (3) JP5102843B2 (en)
KR (1) KR101139413B1 (en)
CN (1) CN101583280B (en)
AU (1) AU2007328034B2 (en)
CA (1) CA2670292C (en)
NZ (1) NZ577130A (en)
RU (1) RU2424245C2 (en)
TW (1) TWI414293B (en)
WO (1) WO2008070176A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009519A1 (en) 2010-07-15 2012-01-19 Efficient Pharma Management Corp. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
WO2012066578A2 (en) 2010-11-18 2012-05-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US11820747B2 (en) 2021-11-02 2023-11-21 Flare Therapeutics Inc. PPARG inverse agonists and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101460207B1 (en) * 2011-12-07 2014-11-11 세종대학교산학협력단 Anticancer agents containing selenophene-fused aromatic compounds
US9624235B2 (en) * 2012-01-31 2017-04-18 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity
CN102675200B (en) * 2012-05-16 2014-04-09 中国药科大学 2-phenyl-4-carbostyril compounds with antineoplastic activity, and preparation method and usage thereof
EP3302488B1 (en) * 2015-06-03 2020-09-30 Tairx, Inc. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry
WO2016201257A2 (en) * 2015-06-10 2016-12-15 The Johns Hopkins University Compositions and methods for identifying adp-ribosylated sites by mass spectrometry

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571822A (en) * 1994-09-30 1996-11-05 The University Of North Carolina At Chapel Hill Antitumor compounds
US6894039B2 (en) * 1996-06-03 2005-05-17 Purdue Research Foundation Selenophene anti-tumor agents
US6897316B2 (en) * 2003-08-08 2005-05-24 China Medical University Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents
US7078552B2 (en) * 2000-04-27 2006-07-18 Arizona Board Of Regents Combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3035650A1 (en) * 1980-09-20 1982-05-06 Hoechst Ag, 6000 Frankfurt (THIONO) (THIOL) PHOSPHOR (PHOSPHON) ACID ESTERS OR ESTERAMIDES OF SUBSTITUTED 4-HYDROXYCHINOLINES, THEIR PRODUCTION AND THEIR USE AS A PEST CONTROL
IL89840A (en) * 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
DE69310367T2 (en) * 1992-07-10 1997-08-14 Glaxo Lab Sa ANILIDE DERIVATIVES
WO1994002145A2 (en) * 1992-07-22 1994-02-03 Genelabs Technologies, Inc. 2-aryl-4-quinolones as antitumor compounds
JPH0733743A (en) * 1993-07-22 1995-02-03 Kyorin Pharmaceut Co Ltd 2-aryl-4-quinolinol derivative
AU2001255538B2 (en) * 2000-04-24 2006-03-30 Bristol-Myers Squibb Company Heterocycles that are inhibitors of IMPDH enzyme
TW490462B (en) * 2000-06-01 2002-06-11 Nat Science Council 2-Phenyl-4-quinazolinones compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
US6569870B1 (en) * 2000-09-25 2003-05-27 The University Of North Carolina At Chapel Hill Fluorinated quinolones as antimitotic and antitumor agents
US6916831B2 (en) * 2003-02-24 2005-07-12 The University Of North Carolina At Chapel Hill Flavone acetic acid analogs and methods of use thereof
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571822A (en) * 1994-09-30 1996-11-05 The University Of North Carolina At Chapel Hill Antitumor compounds
US6894039B2 (en) * 1996-06-03 2005-05-17 Purdue Research Foundation Selenophene anti-tumor agents
US7078552B2 (en) * 2000-04-27 2006-07-18 Arizona Board Of Regents Combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs
US6897316B2 (en) * 2003-08-08 2005-05-24 China Medical University Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2096924A4 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3112348A1 (en) 2010-07-15 2017-01-04 Tairx, Inc. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
US20120015908A1 (en) * 2010-07-15 2012-01-19 Efficient Pharma Management Corporate Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
US8524740B2 (en) 2010-07-15 2013-09-03 Tairx, Inc. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
AU2011279118B2 (en) * 2010-07-15 2014-12-18 Tairx Inc. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
RU2584688C2 (en) * 2010-07-15 2016-05-20 Тэйркс, Инк. Synthesis and anticancer activity of derivatives of aryl and heteroaryl quinolines
WO2012009519A1 (en) 2010-07-15 2012-01-19 Efficient Pharma Management Corp. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
KR101913194B1 (en) * 2010-07-15 2018-10-31 타이알엑스, 아이엔씨. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
WO2012066578A2 (en) 2010-11-18 2012-05-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
EP2640392A2 (en) * 2010-11-18 2013-09-25 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
JP2013542982A (en) * 2010-11-18 2013-11-28 カシナ ライラ イノバ ファーマシューティカルズ プライベート リミテッド Substituted 4- (selenophene-2 (or 3) -ylamino) pyrimidine compounds and methods of use thereof
EP2640392A4 (en) * 2010-11-18 2014-03-12 Kasina Laila Innova Pharmaceuticals Private Ltd Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
KR101817221B1 (en) 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US11820747B2 (en) 2021-11-02 2023-11-21 Flare Therapeutics Inc. PPARG inverse agonists and uses thereof

Also Published As

Publication number Publication date
US20100168064A1 (en) 2010-07-01
CA2670292A1 (en) 2008-06-12
US9023866B2 (en) 2015-05-05
KR101139413B1 (en) 2012-06-22
AU2007328034B2 (en) 2011-03-10
AU2007328034A1 (en) 2008-06-12
TW200831094A (en) 2008-08-01
RU2009124622A (en) 2011-01-20
JP5102843B2 (en) 2012-12-19
EP2096924A4 (en) 2010-09-15
US20130252999A1 (en) 2013-09-26
JP2010512319A (en) 2010-04-22
TWI414293B (en) 2013-11-11
NZ577130A (en) 2010-11-26
JP2013032357A (en) 2013-02-14
EP2096924B1 (en) 2013-02-13
US20130244983A1 (en) 2013-09-19
CN101583280A (en) 2009-11-18
EP2468747B1 (en) 2014-09-03
EP2468747A1 (en) 2012-06-27
JP5501414B2 (en) 2014-05-21
RU2424245C2 (en) 2011-07-20
US9029394B2 (en) 2015-05-12
JP2012214501A (en) 2012-11-08
CA2670292C (en) 2012-01-31
US8440692B2 (en) 2013-05-14
EP2455369B1 (en) 2014-09-03
EP2096924A1 (en) 2009-09-09
CN101583280B (en) 2013-04-24
EP2455369A1 (en) 2012-05-23
KR20090101350A (en) 2009-09-25
US20130253006A1 (en) 2013-09-26
US9023867B2 (en) 2015-05-05
JP5969854B2 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
US9029394B2 (en) 2-phenyl-4-quinolones as anticancer agents
AU724473B2 (en) Tetrahydroquinoline derivatives as EAA antagonists
KR20150079916A (en) Novel amine derivative or salt thereof
KR100210214B1 (en) Substituted (quinoline-2-yl-methoxy)phenylacyl-sulphonamides and process for their preparation and their use in medicines
KR100511626B1 (en) Method for producing quinolinone derivatives
CA2186086A1 (en) Substituted xanthines
NZ200878A (en) Quinoline derivatives and pharmaceutical compositions containing such
WO2004075858A2 (en) Flavone acetic acid analogs and methods of use thereof
US6569870B1 (en) Fluorinated quinolones as antimitotic and antitumor agents
JPH09110866A (en) Heterocyclic aryl-, alkyl-, and cycloalkylacetamide compounds
JPS597168A (en) Carbostyryl derivative
Reisch et al. Acetylene chemistry. Part 27. Palladium catalysed C C bond formation between quinoline and mono‐substituted alkynes: Synthesis of 4‐alkynyl‐2‐bromoquinolines
EP0508347A1 (en) 5,7-Dihydroxy-2-methyl-8-[4-(3-hydroxy-1-(1-propyl)) piperidinyl]-4H-1-benzopyran-4-one, its preparation and its use
JPH059429B2 (en)
JPH0328425B2 (en)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780044796.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07853279

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2670292

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 577130

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2009540310

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3052/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007853279

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007328034

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009124622

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097014196

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007328034

Country of ref document: AU

Date of ref document: 20071207

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12448088

Country of ref document: US